Authors

Latest:

HR-Positive Advances Highlight the Good News in Breast Cancer

Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus.

Jennifer Woyach, MD

Latest:

Dr Woyach on Responses to Pirtobrutinib in CLL/SLL With/Without Prior BCL2 Inhibitor Exposure

Jennifer A Woyach, MD, discusses the efficacy of pirtobrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who progressed on treatment with a covalent BTK inhibitor, including subgroups with or without previous exposure to a BCL2 inhibitor.

Jennifer Wu, MD

Latest:

Salvage Therapy and Emerging Agents in Colorectal Cancer

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.

Jennifer Y. Sheng, MD

Latest:

Oncology Fellow Focuses on Compassionate End-of-Life Care

Due to the misconception surrounding "hospice," many patients with cancer use excess hospital care and intensive care services at the end of life.

Jennifer Yuchen Shih, MD,

Latest:

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Jenny C. Chang, MD

Latest:

Dr. Chang on Genomic Testing in Breast Cancer

Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.

Jenny Pincus, MD

Latest:

Dr. Pincus on Classifying HER2+ Tumors in Breast Cancer

Jenny Pincus, MD, assistant professor of pathology, Northwestern University, Feinberg School of Medicine, discusses the classification of HER2-positive tumors in patients with breast cancer.

Jenny Powers, PhD

Latest:

Combinations With Abemaciclib Show Long-Term Disease Control in Advanced Breast Cancer

Abemaciclib plus tamoxifen, trastuzumab, or one of many endocrine-based therapies demonstrated significant antitumor activity and clinical benefit in patients with advanced breast cancer.

Jens Hillengass, MD

Latest:

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

Jens Huober, MD

Latest:

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Jerald P. Radich, MD

Latest:

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Jeremie Calais, MD, PhD

Latest:

Dr Calais on Controversies in the Treatment of Patients With Prostate Cancer

Jeremie Calais, MD, PhD, discusses controversies and unresolved questions in the treatment of patients with prostate cancer.

Jeremy Abramson, MD

Latest:

Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Jeremy Segal, MD, PhD

Latest:

Dr. Segal on Next-Generation Sequencing for Lung Cancer

Jeremy Segal, MD, PhD, discusses the use of next-generation sequencing for patients with lung cancer.

Jeremy Slade Abramson, MD

Latest:

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

Jeri L. Ashley, RN, Baptist Memorial

Jerome G. Kim, MD

Latest:

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Jerome Galon, PhD

Latest:

Next Steps for Immunoscore in Oncology

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

Jerry Conway

Latest:

The Role of Companion Diagnostic Testing in Payer Decision Making

Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.

Jerry Lanchbury, PhD

Latest:

Jerry Lanchbury, PhD, Describes Myriad's HRD Test

Jerry Lanchbury, PhD, Chief Scientific Officer, Myriad Genetics, Inc., describes the HRD (homologous recombination deficiency) test.